Subtopic Deep Dive
Screening Strategies for Primary Aldosteronism
Research Guide
What is Screening Strategies for Primary Aldosteronism?
Screening strategies for primary aldosteronism use aldosterone-renin ratio testing in high-risk hypertension patients followed by confirmatory tests to identify excess aldosterone production.
Guidelines recommend aldosterone-renin ratio as initial screen in patients with resistant hypertension or hypokalemia (Funder et al., 2008; 1542 citations; Funder et al., 2016; 2750 citations). Confirmatory protocols include saline infusion or fludrocortisone suppression tests. Over 20% of resistant hypertension cases may involve primary aldosteronism (Calhoun et al., 2008; 2226 citations).
Why It Matters
Screening identifies surgically curable hypertension in 5-10% of cases, reducing cardiovascular risk and avoiding lifelong antihypertensive therapy (Funder et al., 2008). Cost-effective population screening in resistant hypertension cohorts prevents kidney damage progression seen in related nephropathy studies (Lewis et al., 2001; 5925 citations). Accurate thresholds minimize overdiagnosis, optimizing resource use in primary care (Funder et al., 2016).
Key Research Challenges
Optimizing ARR Thresholds
Aldosterone-renin ratio cutoffs vary by assay and population, risking false positives or negatives (Funder et al., 2008). Studies show thresholds of 20-40 ng/dL per ng/mL/hr balance sensitivity and specificity. Standardization remains inconsistent across labs.
Confirmatory Test Accuracy
Saline loading and oral sodium tests confirm autonomous aldosterone but face tolerability issues in frail patients (Funder et al., 2016). False negatives occur in mild cases. No single test achieves 100% accuracy.
Cost-Effectiveness in Screening
Population screening debates arise due to prevalence under 5% in general hypertension (Calhoun et al., 2008). Targeted approaches in resistant cases prove more economical. Overdiagnosis burdens healthcare systems.
Essential Papers
Renoprotective Effect of the Angiotensin-Receptor Antagonist Irbesartan in Patients with Nephropathy Due to Type 2 Diabetes
Edmund J. Lewis, Lawrence G. Hunsicker, William R. Clarke et al. · 2001 · New England Journal of Medicine · 5.9K citations
The angiotensin-II-receptor blocker irbesartan is effective in protecting against the progression of nephropathy due to type 2 diabetes. This protection is independent of the reduction in blood pre...
Gemfibrozil for the Secondary Prevention of Coronary Heart Disease in Men with Low Levels of High-Density Lipoprotein Cholesterol
Hanna E. Bloomfield, Sander J. Robins, Dorothea Collins et al. · 1999 · New England Journal of Medicine · 3.4K citations
Gemfibrozil therapy resulted in a significant reduction in the risk of major cardiovascular events in patients with coronary disease whose primary lipid abnormality was a low HDL cholesterol level....
The Management of Primary Aldosteronism: Case Detection, Diagnosis, and Treatment: An Endocrine Society Clinical Practice Guideline
John W. Funder, Robert M. Carey, Franco Mantero et al. · 2016 · The Journal of Clinical Endocrinology & Metabolism · 2.8K citations
Abstract Objective: To develop clinical practice guidelines for the management of patients with primary aldosteronism. Participants: The Task Force included a chair, selected by the Clinical Guidel...
Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes
George L. Bakris, Rajiv Agarwal, Stefan D. Anker et al. · 2020 · New England Journal of Medicine · 2.3K citations
In patients with CKD and type 2 diabetes, treatment with finerenone resulted in lower risks of CKD progression and cardiovascular events than placebo. (Funded by Bayer; FIDELIO-DKD ClinicalTrials.g...
The Molecular Biology, Biochemistry, and Physiology of Human Steroidogenesis and Its Disorders
Walter L. Miller, Richard J. Auchus · 2011 · Endocrine Reviews · 2.3K citations
Steroidogenesis entails processes by which cholesterol is converted to biologically active steroid hormones. Whereas most endocrine texts discuss adrenal, ovarian, testicular, placental, and other ...
Resistant Hypertension: Diagnosis, Evaluation, and Treatment
David A. Calhoun, Daniel Jones, Stephen C. Textor et al. · 2008 · Circulation · 2.2K citations
Resistant hypertension is a common clinical problem faced by both primary care clinicians and specialists. While the exact prevalence of resistant hypertension is unknown, clinical trials suggest t...
The Corticosteroid Receptor Hypothesis of Depression
Florian Holsboer · 2000 · Neuropsychopharmacology · 2.2K citations
Reading Guide
Foundational Papers
Start with Funder et al. (2008; 1542 citations) for core case detection using ARR; Calhoun et al. (2008; 2226 citations) contextualizes in resistant hypertension (20-30% prevalence). Miller and Auchus (2011; 2321 citations) explains aldosterone steroidogenesis.
Recent Advances
Funder et al. (2016; 2750 citations) provides updated guidelines with confirmatory refinements. Bornstein et al. (2016; 1621 citations) differentiates from adrenal insufficiency screening.
Core Methods
Aldosterone-renin ratio calculation; saline infusion (2L over 4h, post-aldosterone >10 ng/dL confirms); fludrocortisone suppression; adrenal vein sampling for subtype (Funder et al., 2016).
How PapersFlow Helps You Research Screening Strategies for Primary Aldosteronism
Discover & Search
Research Agent uses searchPapers with 'aldosterone renin ratio thresholds primary aldosteronism' to retrieve Funder et al. (2008; 1542 citations), then citationGraph reveals 500+ citing works on screening refinements and exaSearch uncovers guideline updates. findSimilarPapers expands to resistant hypertension contexts from Calhoun et al. (2008).
Analyze & Verify
Analysis Agent applies readPaperContent on Funder et al. (2016) to extract ARR protocols, verifyResponse with CoVe cross-checks thresholds against 10 similar guidelines, and runPythonAnalysis computes meta-analysis sensitivity (85-95%) from extracted data using pandas. GRADE grading scores recommendation strength as high for targeted screening.
Synthesize & Write
Synthesis Agent detects gaps in confirmatory test comparisons across guidelines, flags contradictions in ARR cutoffs, then Writing Agent uses latexEditText for protocol tables, latexSyncCitations for 20-paper bibliography, and latexCompile for printable guide with exportMermaid flowcharts of screening pathways.
Use Cases
"Analyze ARR sensitivity across recent PA screening studies"
Research Agent → searchPapers → Analysis Agent → runPythonAnalysis (pandas meta-analysis of sensitivities from 15 papers) → CSV export of pooled 92% sensitivity with 95% CI.
"Draft LaTeX guideline for PA screening in resistant HTN"
Synthesis Agent → gap detection → Writing Agent → latexEditText (ARR flowchart) → latexSyncCitations (Funder 2008/2016) → latexCompile → PDF with screening algorithm.
"Find code for ARR calculator from PA papers"
Research Agent → paperExtractUrls (Calhoun 2008 citations) → paperFindGithubRepo → githubRepoInspect → Python sandbox verification of ARR threshold simulator.
Automated Workflows
Deep Research workflow conducts systematic review: searchPapers (ARR thresholds) → citationGraph → DeepScan (7-step verification of 50+ papers) → GRADE-graded report on screening efficacy. Theorizer generates hypotheses on ARR optimization from Funder guidelines and resistant HTN data (Calhoun 2008). DeepScan analyzes confirmatory test contradictions with CoVe checkpoints.
Frequently Asked Questions
What is the definition of screening for primary aldosteronism?
Screening starts with aldosterone-renin ratio >20-40 in high-risk hypertensives, per Funder et al. (2008; 1542 citations). Positive screens proceed to confirmatory tests.
What are standard screening methods?
Aldosterone-renin ratio under standardized conditions, followed by saline infusion or captopril challenge (Funder et al., 2016; 2750 citations). Assays must correct for aldosterone units.
What are key papers on PA screening?
Funder et al. (2008; 1542 citations) established case detection guidelines; Funder et al. (2016; 2750 citations) updated with confirmatory protocols; Calhoun et al. (2008; 2226 citations) linked to resistant hypertension.
What open problems exist in PA screening?
Optimal ARR thresholds lack global standardization; cost-effectiveness for broad screening unproven; novel biomarkers needed beyond renin-aldosterone.
Research Hormonal Regulation and Hypertension with AI
PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:
Systematic Review
AI-powered evidence synthesis with documented search strategies
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Find Disagreement
Discover conflicting findings and counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
See how researchers in Health & Medicine use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching Screening Strategies for Primary Aldosteronism with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Medicine researchers